cigna and glp 1 coverage prior authorization for Ozempic, Wegovy, Mounjaro & Zepbound Cigna dropping GLP-1 obesity drug

At the maximum 15mg dose, average weight loss reached 22.5%

An increased risk of NAFLD (Non-alcoholic fatty liver disease) is seen in obese patients, with annual burdens in the treatment of NAFLD estimated to be in the hundreds of billions for the US [10]

Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review

Evaluation of the therapeutic effect of melittin peptide on the ulcerative colitis mouse model

The cardiovascular benefits, demonstrated in the SELECT trial showing reduced heart attack and stroke risk with semaglutide, actually argue in favor of continued use for people with cardiovascular risk factors